Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients

Objective: This study compared the safety and efficacy of Safacto® versus xyntha® in patients with severe hemophilia A. Methods: Thirty-three male patients with severe hemophilia A were randomly divided into two groups. Seventeen patients received Safacto® and 16 patients...

Full description

Bibliographic Details
Main Authors: Hassan Abolghasemi, MD, Yunes Panahi, PhD, Minoo. Ahmadinejad, MD, Gholamreza Toogeh, MD, Mehran Karimi, MD, Aziz Eghbali, MD, Nargess Bigom Mirbehbahani, MD, Bighan Keikhaei Dehdezi, MD, Zahra Badiee, MD, Hamid Hoorfar, MD, Peyman Eshghi, MD, Nader Maghsoudi, PhD, Amirhossein Sahebkar, PhD, Mohammad Gholami- Fesharaki, PhD
Format: Article
Language:English
Published: Korean Pharmacopuncture Institute 2018-06-01
Series:Journal of Pharmacopuncture
Subjects:
hemophilia a
recombinant factor viii
safacto
xyntha
Online Access:http://www.journal-pharm.com/sub/view/244

Internet

http://www.journal-pharm.com/sub/view/244

Similar Items